Pegloticase Therapy Shows Low Risk of CV and TE Events
The following is a summary of “Treatment-Emergent Major Adverse Cardiovascular and Thromboembolic Events were Infrequent During Clinical Trials of Pegloticase,” published in the January 2025 issue of Rheumatology by Troum et al. Maintaining serum urate (SU) levels...